nodes	percent_of_prediction	percent_of_DWPC	metapath
Pioglitazone—SLCO1B3—Docetaxel—skin cancer	0.117	0.163	CbGbCtD
Pioglitazone—CYP2C8—Vismodegib—skin cancer	0.106	0.148	CbGbCtD
Pioglitazone—CYP2C19—Vismodegib—skin cancer	0.0891	0.124	CbGbCtD
Pioglitazone—CYP2C9—Vismodegib—skin cancer	0.0741	0.103	CbGbCtD
Pioglitazone—CYP3A4—Temozolomide—skin cancer	0.0622	0.0867	CbGbCtD
Pioglitazone—CYP3A4—Imiquimod—skin cancer	0.0622	0.0867	CbGbCtD
Pioglitazone—CYP2D6—Vemurafenib—skin cancer	0.0536	0.0747	CbGbCtD
Pioglitazone—CYP3A4—Vismodegib—skin cancer	0.0431	0.0601	CbGbCtD
Pioglitazone—CYP2C8—Fluorouracil—skin cancer	0.0377	0.0526	CbGbCtD
Pioglitazone—CYP3A4—Vemurafenib—skin cancer	0.0341	0.0475	CbGbCtD
Pioglitazone—CYP2C9—Fluorouracil—skin cancer	0.0263	0.0367	CbGbCtD
Pioglitazone—CYP3A4—Docetaxel—skin cancer	0.0117	0.0163	CbGbCtD
Pioglitazone—PPARG—dermis—skin cancer	0.0102	0.154	CbGeAlD
Pioglitazone—PPARG—leg—skin cancer	0.00671	0.102	CbGeAlD
Pioglitazone—PPARG—forelimb—skin cancer	0.00666	0.101	CbGeAlD
Pioglitazone—PPARG—hindlimb—skin cancer	0.006	0.0908	CbGeAlD
Pioglitazone—PPARG—appendage—skin cancer	0.00514	0.0779	CbGeAlD
Pioglitazone—PPARG—endothelium—skin cancer	0.0031	0.047	CbGeAlD
Pioglitazone—PPARG—blood vessel—skin cancer	0.00286	0.0433	CbGeAlD
Pioglitazone—PPARG—nipple—skin cancer	0.00207	0.0313	CbGeAlD
Pioglitazone—PPARG—neck—skin cancer	0.00205	0.031	CbGeAlD
Pioglitazone—PTGS1—endothelium—skin cancer	0.00166	0.0251	CbGeAlD
Pioglitazone—PTGS1—blood vessel—skin cancer	0.00153	0.0232	CbGeAlD
Pioglitazone—PPARG—connective tissue—skin cancer	0.00147	0.0222	CbGeAlD
Pioglitazone—PPARG—epithelium—skin cancer	0.00139	0.0211	CbGeAlD
Pioglitazone—PPARG—skin of body—skin cancer	0.00133	0.0201	CbGeAlD
Pioglitazone—PPARG—mammalian vulva—skin cancer	0.00121	0.0183	CbGeAlD
Pioglitazone—SLCO1B1—female reproductive system—skin cancer	0.0012	0.0182	CbGeAlD
Pioglitazone—PTGS1—nipple—skin cancer	0.00111	0.0167	CbGeAlD
Pioglitazone—PPARG—lymphoid tissue—skin cancer	0.00107	0.0162	CbGeAlD
Pioglitazone—PPARG—female reproductive system—skin cancer	0.00104	0.0157	CbGeAlD
Pioglitazone—Oedema peripheral—Vemurafenib—skin cancer	0.00103	0.00476	CcSEcCtD
Pioglitazone—Connective tissue disorder—Vemurafenib—skin cancer	0.00103	0.00475	CcSEcCtD
Pioglitazone—Erectile dysfunction—Imiquimod—skin cancer	0.00103	0.00474	CcSEcCtD
Pioglitazone—Injury—Bleomycin—skin cancer	0.000997	0.0046	CcSEcCtD
Pioglitazone—Infestation—Imiquimod—skin cancer	0.000994	0.00459	CcSEcCtD
Pioglitazone—Infestation NOS—Imiquimod—skin cancer	0.000994	0.00459	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Imiquimod—skin cancer	0.00098	0.00452	CcSEcCtD
Pioglitazone—Eye disorder—Vemurafenib—skin cancer	0.000978	0.00452	CcSEcCtD
Pioglitazone—Myocardial infarction—Imiquimod—skin cancer	0.000975	0.0045	CcSEcCtD
Pioglitazone—Cardiac disorder—Vemurafenib—skin cancer	0.000971	0.00448	CcSEcCtD
Pioglitazone—Urinary tract infection—Imiquimod—skin cancer	0.000966	0.00446	CcSEcCtD
Pioglitazone—Neoplasm—Temozolomide—skin cancer	0.000963	0.00445	CcSEcCtD
Pioglitazone—Hepatic failure—Dactinomycin—skin cancer	0.000951	0.00439	CcSEcCtD
Pioglitazone—Mediastinal disorder—Vemurafenib—skin cancer	0.000943	0.00435	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Bleomycin—skin cancer	0.000935	0.00432	CcSEcCtD
Pioglitazone—Sinusitis—Imiquimod—skin cancer	0.000933	0.00431	CcSEcCtD
Pioglitazone—Abnormal vision—Temozolomide—skin cancer	0.000929	0.00429	CcSEcCtD
Pioglitazone—Malnutrition—Vemurafenib—skin cancer	0.000911	0.00421	CcSEcCtD
Pioglitazone—Pharyngitis—Imiquimod—skin cancer	0.000886	0.00409	CcSEcCtD
Pioglitazone—Urinary tract disorder—Imiquimod—skin cancer	0.000881	0.00407	CcSEcCtD
Pioglitazone—Back pain—Vemurafenib—skin cancer	0.000881	0.00407	CcSEcCtD
Pioglitazone—Myocardial ischaemia—Docetaxel—skin cancer	0.000881	0.00407	CcSEcCtD
Pioglitazone—Connective tissue disorder—Imiquimod—skin cancer	0.000877	0.00405	CcSEcCtD
Pioglitazone—Urethral disorder—Imiquimod—skin cancer	0.000875	0.00404	CcSEcCtD
Pioglitazone—Gastroenteritis—Temozolomide—skin cancer	0.000872	0.00403	CcSEcCtD
Pioglitazone—PPARG—head—skin cancer	0.000865	0.0131	CbGeAlD
Pioglitazone—Asthenia—Vismodegib—skin cancer	0.000863	0.00399	CcSEcCtD
Pioglitazone—Hepatic failure—Temozolomide—skin cancer	0.00086	0.00397	CcSEcCtD
Pioglitazone—Visual impairment—Imiquimod—skin cancer	0.00086	0.00397	CcSEcCtD
Pioglitazone—Eye disorder—Imiquimod—skin cancer	0.000834	0.00385	CcSEcCtD
Pioglitazone—Diarrhoea—Vismodegib—skin cancer	0.000823	0.0038	CcSEcCtD
Pioglitazone—Immune system disorder—Imiquimod—skin cancer	0.000806	0.00372	CcSEcCtD
Pioglitazone—Mediastinal disorder—Imiquimod—skin cancer	0.000804	0.00371	CcSEcCtD
Pioglitazone—Liver function test abnormal—Dactinomycin—skin cancer	0.000789	0.00364	CcSEcCtD
Pioglitazone—PTGS1—connective tissue—skin cancer	0.000785	0.0119	CbGeAlD
Pioglitazone—Malnutrition—Imiquimod—skin cancer	0.000777	0.00359	CcSEcCtD
Pioglitazone—Arthralgia—Vemurafenib—skin cancer	0.000776	0.00358	CcSEcCtD
Pioglitazone—Myalgia—Vemurafenib—skin cancer	0.000776	0.00358	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00077	0.00356	CcSEcCtD
Pioglitazone—Back pain—Imiquimod—skin cancer	0.000752	0.00347	CcSEcCtD
Pioglitazone—PTGS1—epithelium—skin cancer	0.000745	0.0113	CbGeAlD
Pioglitazone—Anaphylactic shock—Vemurafenib—skin cancer	0.000744	0.00343	CcSEcCtD
Pioglitazone—Infection—Vemurafenib—skin cancer	0.000739	0.00341	CcSEcCtD
Pioglitazone—Cardiac failure—Fluorouracil—skin cancer	0.00073	0.00337	CcSEcCtD
Pioglitazone—Nervous system disorder—Vemurafenib—skin cancer	0.000729	0.00337	CcSEcCtD
Pioglitazone—Skin disorder—Vemurafenib—skin cancer	0.000722	0.00333	CcSEcCtD
Pioglitazone—Ill-defined disorder—Imiquimod—skin cancer	0.000721	0.00333	CcSEcCtD
Pioglitazone—Weight decreased—Bleomycin—skin cancer	0.000717	0.00331	CcSEcCtD
Pioglitazone—Angioedema—Imiquimod—skin cancer	0.00071	0.00328	CcSEcCtD
Pioglitazone—PTGS1—skin of body—skin cancer	0.000709	0.0107	CbGeAlD
Pioglitazone—Malaise—Imiquimod—skin cancer	0.000701	0.00323	CcSEcCtD
Pioglitazone—Breast disorder—Temozolomide—skin cancer	0.000699	0.00323	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Bleomycin—skin cancer	0.000696	0.00321	CcSEcCtD
Pioglitazone—Myocardial infarction—Bleomycin—skin cancer	0.000692	0.0032	CcSEcCtD
Pioglitazone—CYP2C8—female reproductive system—skin cancer	0.000683	0.0103	CbGeAlD
Pioglitazone—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000682	0.00315	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000677	0.00313	CcSEcCtD
Pioglitazone—Haematuria—Bleomycin—skin cancer	0.000673	0.00311	CcSEcCtD
Pioglitazone—Fluid retention—Docetaxel—skin cancer	0.000672	0.0031	CcSEcCtD
Pioglitazone—Hypertension—Imiquimod—skin cancer	0.000671	0.0031	CcSEcCtD
Pioglitazone—Chest pain—Imiquimod—skin cancer	0.000661	0.00305	CcSEcCtD
Pioglitazone—Arthralgia—Imiquimod—skin cancer	0.000661	0.00305	CcSEcCtD
Pioglitazone—Myalgia—Imiquimod—skin cancer	0.000661	0.00305	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000657	0.00303	CcSEcCtD
Pioglitazone—Discomfort—Imiquimod—skin cancer	0.000654	0.00302	CcSEcCtD
Pioglitazone—PTGS1—mammalian vulva—skin cancer	0.000646	0.00978	CbGeAlD
Pioglitazone—Bronchitis—Temozolomide—skin cancer	0.000643	0.00297	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000642	0.00296	CcSEcCtD
Pioglitazone—Fatigue—Vemurafenib—skin cancer	0.000641	0.00296	CcSEcCtD
Pioglitazone—Neoplasm—Docetaxel—skin cancer	0.00064	0.00296	CcSEcCtD
Pioglitazone—Oedema—Imiquimod—skin cancer	0.000634	0.00293	CcSEcCtD
Pioglitazone—Hypoaesthesia—Bleomycin—skin cancer	0.000631	0.00291	CcSEcCtD
Pioglitazone—Pulmonary oedema—Docetaxel—skin cancer	0.00063	0.00291	CcSEcCtD
Pioglitazone—Infection—Imiquimod—skin cancer	0.00063	0.00291	CcSEcCtD
Pioglitazone—Nervous system disorder—Imiquimod—skin cancer	0.000622	0.00287	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Temozolomide—skin cancer	0.000621	0.00287	CcSEcCtD
Pioglitazone—Skin disorder—Imiquimod—skin cancer	0.000616	0.00284	CcSEcCtD
Pioglitazone—Erectile dysfunction—Temozolomide—skin cancer	0.000615	0.00284	CcSEcCtD
Pioglitazone—Hyperhidrosis—Imiquimod—skin cancer	0.000613	0.00283	CcSEcCtD
Pioglitazone—Weight increased—Temozolomide—skin cancer	0.000608	0.00281	CcSEcCtD
Pioglitazone—CYP2C9—female reproductive system—skin cancer	0.000606	0.00918	CbGeAlD
Pioglitazone—PPARG—lymph node—skin cancer	0.000606	0.00917	CbGeAlD
Pioglitazone—Weight decreased—Temozolomide—skin cancer	0.000605	0.00279	CcSEcCtD
Pioglitazone—Hyperglycaemia—Temozolomide—skin cancer	0.000603	0.00278	CcSEcCtD
Pioglitazone—Angina pectoris—Fluorouracil—skin cancer	0.0006	0.00277	CcSEcCtD
Pioglitazone—Infestation NOS—Temozolomide—skin cancer	0.000596	0.00275	CcSEcCtD
Pioglitazone—Infestation—Temozolomide—skin cancer	0.000596	0.00275	CcSEcCtD
Pioglitazone—Hepatitis—Dactinomycin—skin cancer	0.000591	0.00273	CcSEcCtD
Pioglitazone—Pharyngitis—Dactinomycin—skin cancer	0.000587	0.00271	CcSEcCtD
Pioglitazone—Urinary tract infection—Temozolomide—skin cancer	0.000579	0.00267	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000578	0.00267	CcSEcCtD
Pioglitazone—Insomnia—Imiquimod—skin cancer	0.000573	0.00265	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000572	0.00264	CcSEcCtD
Pioglitazone—Hepatic failure—Docetaxel—skin cancer	0.000572	0.00264	CcSEcCtD
Pioglitazone—Cardiac failure congestive—Docetaxel—skin cancer	0.000567	0.00262	CcSEcCtD
Pioglitazone—Dyspnoea—Imiquimod—skin cancer	0.000565	0.00261	CcSEcCtD
Pioglitazone—Sinusitis—Temozolomide—skin cancer	0.000559	0.00258	CcSEcCtD
Pioglitazone—PTGS1—female reproductive system—skin cancer	0.000554	0.00838	CbGeAlD
Pioglitazone—Infestation NOS—Fluorouracil—skin cancer	0.000549	0.00253	CcSEcCtD
Pioglitazone—Infestation—Fluorouracil—skin cancer	0.000549	0.00253	CcSEcCtD
Pioglitazone—Hypersensitivity—Vemurafenib—skin cancer	0.000548	0.00253	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Imiquimod—skin cancer	0.000547	0.00253	CcSEcCtD
Pioglitazone—Fatigue—Imiquimod—skin cancer	0.000547	0.00252	CcSEcCtD
Pioglitazone—Visual disturbance—Docetaxel—skin cancer	0.000543	0.0025	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Fluorouracil—skin cancer	0.000541	0.0025	CcSEcCtD
Pioglitazone—Myocardial infarction—Fluorouracil—skin cancer	0.000538	0.00248	CcSEcCtD
Pioglitazone—Hepatitis—Temozolomide—skin cancer	0.000535	0.00247	CcSEcCtD
Pioglitazone—Urinary tract infection—Fluorouracil—skin cancer	0.000534	0.00246	CcSEcCtD
Pioglitazone—Asthenia—Vemurafenib—skin cancer	0.000533	0.00246	CcSEcCtD
Pioglitazone—Hypoaesthesia—Temozolomide—skin cancer	0.000532	0.00246	CcSEcCtD
Pioglitazone—Pharyngitis—Temozolomide—skin cancer	0.000531	0.00245	CcSEcCtD
Pioglitazone—Urinary tract disorder—Temozolomide—skin cancer	0.000528	0.00244	CcSEcCtD
Pioglitazone—Oedema peripheral—Temozolomide—skin cancer	0.000527	0.00243	CcSEcCtD
Pioglitazone—Cardiac failure—Docetaxel—skin cancer	0.000527	0.00243	CcSEcCtD
Pioglitazone—Connective tissue disorder—Temozolomide—skin cancer	0.000526	0.00243	CcSEcCtD
Pioglitazone—Urethral disorder—Temozolomide—skin cancer	0.000524	0.00242	CcSEcCtD
Pioglitazone—Feeling abnormal—Imiquimod—skin cancer	0.000523	0.00241	CcSEcCtD
Pioglitazone—Visual impairment—Temozolomide—skin cancer	0.000515	0.00238	CcSEcCtD
Pioglitazone—Sinusitis—Fluorouracil—skin cancer	0.000515	0.00238	CcSEcCtD
Pioglitazone—Pain in extremity—Docetaxel—skin cancer	0.000514	0.00237	CcSEcCtD
Pioglitazone—Ill-defined disorder—Bleomycin—skin cancer	0.000512	0.00236	CcSEcCtD
Pioglitazone—Anaemia—Bleomycin—skin cancer	0.00051	0.00236	CcSEcCtD
Pioglitazone—Diarrhoea—Vemurafenib—skin cancer	0.000509	0.00235	CcSEcCtD
Pioglitazone—Urticaria—Imiquimod—skin cancer	0.000504	0.00233	CcSEcCtD
Pioglitazone—Eye disorder—Temozolomide—skin cancer	0.0005	0.00231	CcSEcCtD
Pioglitazone—Malaise—Bleomycin—skin cancer	0.000498	0.0023	CcSEcCtD
Pioglitazone—Cardiac disorder—Temozolomide—skin cancer	0.000496	0.00229	CcSEcCtD
Pioglitazone—Dizziness—Vemurafenib—skin cancer	0.000492	0.00227	CcSEcCtD
Pioglitazone—Hypoaesthesia—Fluorouracil—skin cancer	0.00049	0.00226	CcSEcCtD
Pioglitazone—Pharyngitis—Fluorouracil—skin cancer	0.000489	0.00226	CcSEcCtD
Pioglitazone—Immune system disorder—Temozolomide—skin cancer	0.000483	0.00223	CcSEcCtD
Pioglitazone—Mediastinal disorder—Temozolomide—skin cancer	0.000482	0.00223	CcSEcCtD
Pioglitazone—Ill-defined disorder—Dactinomycin—skin cancer	0.000478	0.00221	CcSEcCtD
Pioglitazone—Anaemia—Dactinomycin—skin cancer	0.000476	0.0022	CcSEcCtD
Pioglitazone—Liver function test abnormal—Docetaxel—skin cancer	0.000475	0.00219	CcSEcCtD
Pioglitazone—Chest pain—Bleomycin—skin cancer	0.00047	0.00217	CcSEcCtD
Pioglitazone—Myalgia—Bleomycin—skin cancer	0.00047	0.00217	CcSEcCtD
Pioglitazone—Abdominal pain upper—Docetaxel—skin cancer	0.00047	0.00217	CcSEcCtD
Pioglitazone—Hypersensitivity—Imiquimod—skin cancer	0.000467	0.00216	CcSEcCtD
Pioglitazone—Headache—Vemurafenib—skin cancer	0.000466	0.00215	CcSEcCtD
Pioglitazone—Malnutrition—Temozolomide—skin cancer	0.000466	0.00215	CcSEcCtD
Pioglitazone—Breast disorder—Docetaxel—skin cancer	0.000465	0.00215	CcSEcCtD
Pioglitazone—Discomfort—Bleomycin—skin cancer	0.000464	0.00214	CcSEcCtD
Pioglitazone—Malaise—Dactinomycin—skin cancer	0.000464	0.00214	CcSEcCtD
Pioglitazone—PTGS1—head—skin cancer	0.000462	0.007	CbGeAlD
Pioglitazone—CYP3A4—female reproductive system—skin cancer	0.000462	0.007	CbGeAlD
Pioglitazone—CYP2D6—female reproductive system—skin cancer	0.000455	0.00689	CbGeAlD
Pioglitazone—Asthenia—Imiquimod—skin cancer	0.000455	0.0021	CcSEcCtD
Pioglitazone—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000453	0.00209	CcSEcCtD
Pioglitazone—Anaphylactic shock—Bleomycin—skin cancer	0.00045	0.00208	CcSEcCtD
Pioglitazone—Oedema—Bleomycin—skin cancer	0.00045	0.00208	CcSEcCtD
Pioglitazone—Back pain—Temozolomide—skin cancer	0.00045	0.00208	CcSEcCtD
Pioglitazone—Infection—Bleomycin—skin cancer	0.000448	0.00207	CcSEcCtD
Pioglitazone—Myalgia—Dactinomycin—skin cancer	0.000438	0.00202	CcSEcCtD
Pioglitazone—Diarrhoea—Imiquimod—skin cancer	0.000434	0.002	CcSEcCtD
Pioglitazone—Discomfort—Dactinomycin—skin cancer	0.000433	0.002	CcSEcCtD
Pioglitazone—Angina pectoris—Docetaxel—skin cancer	0.000433	0.002	CcSEcCtD
Pioglitazone—Ill-defined disorder—Temozolomide—skin cancer	0.000432	0.00199	CcSEcCtD
Pioglitazone—Anaemia—Temozolomide—skin cancer	0.00043	0.00199	CcSEcCtD
Pioglitazone—Angioedema—Temozolomide—skin cancer	0.000425	0.00196	CcSEcCtD
Pioglitazone—Oedema—Dactinomycin—skin cancer	0.00042	0.00194	CcSEcCtD
Pioglitazone—Malaise—Temozolomide—skin cancer	0.00042	0.00194	CcSEcCtD
Pioglitazone—Dizziness—Imiquimod—skin cancer	0.000419	0.00194	CcSEcCtD
Pioglitazone—Vertigo—Temozolomide—skin cancer	0.000418	0.00193	CcSEcCtD
Pioglitazone—Infection—Dactinomycin—skin cancer	0.000417	0.00193	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00041	0.00189	CcSEcCtD
Pioglitazone—Weight increased—Docetaxel—skin cancer	0.000404	0.00187	CcSEcCtD
Pioglitazone—Weight decreased—Docetaxel—skin cancer	0.000402	0.00186	CcSEcCtD
Pioglitazone—Hypertension—Temozolomide—skin cancer	0.000402	0.00186	CcSEcCtD
Pioglitazone—Dyspnoea—Bleomycin—skin cancer	0.000402	0.00185	CcSEcCtD
Pioglitazone—Headache—Imiquimod—skin cancer	0.000397	0.00183	CcSEcCtD
Pioglitazone—Anaemia—Fluorouracil—skin cancer	0.000396	0.00183	CcSEcCtD
Pioglitazone—Arthralgia—Temozolomide—skin cancer	0.000396	0.00183	CcSEcCtD
Pioglitazone—Myalgia—Temozolomide—skin cancer	0.000396	0.00183	CcSEcCtD
Pioglitazone—Infestation—Docetaxel—skin cancer	0.000396	0.00183	CcSEcCtD
Pioglitazone—Infestation NOS—Docetaxel—skin cancer	0.000396	0.00183	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000394	0.00182	CcSEcCtD
Pioglitazone—Discomfort—Temozolomide—skin cancer	0.000392	0.00181	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Docetaxel—skin cancer	0.000391	0.0018	CcSEcCtD
Pioglitazone—Myocardial infarction—Docetaxel—skin cancer	0.000388	0.00179	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000383	0.00177	CcSEcCtD
Pioglitazone—CYP2D6—head—skin cancer	0.00038	0.00575	CbGeAlD
Pioglitazone—Anaphylactic shock—Temozolomide—skin cancer	0.00038	0.00175	CcSEcCtD
Pioglitazone—Oedema—Temozolomide—skin cancer	0.00038	0.00175	CcSEcCtD
Pioglitazone—Infection—Temozolomide—skin cancer	0.000377	0.00174	CcSEcCtD
Pioglitazone—Nervous system disorder—Temozolomide—skin cancer	0.000373	0.00172	CcSEcCtD
Pioglitazone—Feeling abnormal—Bleomycin—skin cancer	0.000371	0.00171	CcSEcCtD
Pioglitazone—Skin disorder—Temozolomide—skin cancer	0.000369	0.0017	CcSEcCtD
Pioglitazone—Hyperhidrosis—Temozolomide—skin cancer	0.000367	0.0017	CcSEcCtD
Pioglitazone—Chest pain—Fluorouracil—skin cancer	0.000365	0.00169	CcSEcCtD
Pioglitazone—Myalgia—Fluorouracil—skin cancer	0.000365	0.00169	CcSEcCtD
Pioglitazone—Fatigue—Dactinomycin—skin cancer	0.000362	0.00167	CcSEcCtD
Pioglitazone—Discomfort—Fluorouracil—skin cancer	0.000361	0.00167	CcSEcCtD
Pioglitazone—Urticaria—Bleomycin—skin cancer	0.000358	0.00165	CcSEcCtD
Pioglitazone—Hepatitis—Docetaxel—skin cancer	0.000356	0.00164	CcSEcCtD
Pioglitazone—Hypoaesthesia—Docetaxel—skin cancer	0.000354	0.00163	CcSEcCtD
Pioglitazone—Pharyngitis—Docetaxel—skin cancer	0.000353	0.00163	CcSEcCtD
Pioglitazone—Urinary tract disorder—Docetaxel—skin cancer	0.000351	0.00162	CcSEcCtD
Pioglitazone—Oedema peripheral—Docetaxel—skin cancer	0.00035	0.00162	CcSEcCtD
Pioglitazone—Anaphylactic shock—Fluorouracil—skin cancer	0.00035	0.00162	CcSEcCtD
Pioglitazone—Oedema—Fluorouracil—skin cancer	0.00035	0.00162	CcSEcCtD
Pioglitazone—Connective tissue disorder—Docetaxel—skin cancer	0.00035	0.00161	CcSEcCtD
Pioglitazone—Urethral disorder—Docetaxel—skin cancer	0.000349	0.00161	CcSEcCtD
Pioglitazone—Infection—Fluorouracil—skin cancer	0.000348	0.00161	CcSEcCtD
Pioglitazone—Feeling abnormal—Dactinomycin—skin cancer	0.000346	0.0016	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000346	0.0016	CcSEcCtD
Pioglitazone—Insomnia—Temozolomide—skin cancer	0.000344	0.00159	CcSEcCtD
Pioglitazone—Nervous system disorder—Fluorouracil—skin cancer	0.000343	0.00159	CcSEcCtD
Pioglitazone—Visual impairment—Docetaxel—skin cancer	0.000343	0.00158	CcSEcCtD
Pioglitazone—Dyspnoea—Temozolomide—skin cancer	0.000339	0.00156	CcSEcCtD
Pioglitazone—Eye disorder—Docetaxel—skin cancer	0.000332	0.00153	CcSEcCtD
Pioglitazone—Hypersensitivity—Bleomycin—skin cancer	0.000332	0.00153	CcSEcCtD
Pioglitazone—Cardiac disorder—Docetaxel—skin cancer	0.00033	0.00152	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Temozolomide—skin cancer	0.000328	0.00151	CcSEcCtD
Pioglitazone—Fatigue—Temozolomide—skin cancer	0.000328	0.00151	CcSEcCtD
Pioglitazone—PTGS1—lymph node—skin cancer	0.000324	0.0049	CbGeAlD
Pioglitazone—Asthenia—Bleomycin—skin cancer	0.000323	0.00149	CcSEcCtD
Pioglitazone—Immune system disorder—Docetaxel—skin cancer	0.000321	0.00148	CcSEcCtD
Pioglitazone—Mediastinal disorder—Docetaxel—skin cancer	0.000321	0.00148	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000319	0.00147	CcSEcCtD
Pioglitazone—Insomnia—Fluorouracil—skin cancer	0.000317	0.00146	CcSEcCtD
Pioglitazone—Feeling abnormal—Temozolomide—skin cancer	0.000313	0.00145	CcSEcCtD
Pioglitazone—Dyspnoea—Fluorouracil—skin cancer	0.000312	0.00144	CcSEcCtD
Pioglitazone—Malnutrition—Docetaxel—skin cancer	0.00031	0.00143	CcSEcCtD
Pioglitazone—Hypersensitivity—Dactinomycin—skin cancer	0.00031	0.00143	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000302	0.0014	CcSEcCtD
Pioglitazone—Urticaria—Temozolomide—skin cancer	0.000302	0.00139	CcSEcCtD
Pioglitazone—Asthenia—Dactinomycin—skin cancer	0.000301	0.00139	CcSEcCtD
Pioglitazone—Back pain—Docetaxel—skin cancer	0.000299	0.00138	CcSEcCtD
Pioglitazone—Muscle spasms—Docetaxel—skin cancer	0.000298	0.00137	CcSEcCtD
Pioglitazone—Feeling abnormal—Fluorouracil—skin cancer	0.000289	0.00133	CcSEcCtD
Pioglitazone—Diarrhoea—Dactinomycin—skin cancer	0.000287	0.00133	CcSEcCtD
Pioglitazone—Anaemia—Docetaxel—skin cancer	0.000286	0.00132	CcSEcCtD
Pioglitazone—Hypersensitivity—Temozolomide—skin cancer	0.00028	0.00129	CcSEcCtD
Pioglitazone—Urticaria—Fluorouracil—skin cancer	0.000278	0.00128	CcSEcCtD
Pioglitazone—Asthenia—Temozolomide—skin cancer	0.000273	0.00126	CcSEcCtD
Pioglitazone—Hypertension—Docetaxel—skin cancer	0.000267	0.00123	CcSEcCtD
Pioglitazone—Myalgia—Docetaxel—skin cancer	0.000264	0.00122	CcSEcCtD
Pioglitazone—Arthralgia—Docetaxel—skin cancer	0.000264	0.00122	CcSEcCtD
Pioglitazone—Chest pain—Docetaxel—skin cancer	0.000264	0.00122	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000262	0.00121	CcSEcCtD
Pioglitazone—Diarrhoea—Temozolomide—skin cancer	0.00026	0.0012	CcSEcCtD
Pioglitazone—Hypersensitivity—Fluorouracil—skin cancer	0.000258	0.00119	CcSEcCtD
Pioglitazone—Oedema—Docetaxel—skin cancer	0.000253	0.00117	CcSEcCtD
Pioglitazone—Anaphylactic shock—Docetaxel—skin cancer	0.000253	0.00117	CcSEcCtD
Pioglitazone—Dizziness—Temozolomide—skin cancer	0.000251	0.00116	CcSEcCtD
Pioglitazone—Infection—Docetaxel—skin cancer	0.000251	0.00116	CcSEcCtD
Pioglitazone—Nervous system disorder—Docetaxel—skin cancer	0.000248	0.00114	CcSEcCtD
Pioglitazone—Skin disorder—Docetaxel—skin cancer	0.000245	0.00113	CcSEcCtD
Pioglitazone—Diarrhoea—Fluorouracil—skin cancer	0.00024	0.00111	CcSEcCtD
Pioglitazone—Headache—Temozolomide—skin cancer	0.000238	0.0011	CcSEcCtD
Pioglitazone—Dizziness—Fluorouracil—skin cancer	0.000232	0.00107	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00023	0.00106	CcSEcCtD
Pioglitazone—Insomnia—Docetaxel—skin cancer	0.000229	0.00106	CcSEcCtD
Pioglitazone—Dyspnoea—Docetaxel—skin cancer	0.000225	0.00104	CcSEcCtD
Pioglitazone—Headache—Fluorouracil—skin cancer	0.000219	0.00101	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Docetaxel—skin cancer	0.000218	0.00101	CcSEcCtD
Pioglitazone—Fatigue—Docetaxel—skin cancer	0.000218	0.00101	CcSEcCtD
Pioglitazone—Feeling abnormal—Docetaxel—skin cancer	0.000208	0.000961	CcSEcCtD
Pioglitazone—Hypersensitivity—Docetaxel—skin cancer	0.000186	0.00086	CcSEcCtD
Pioglitazone—Asthenia—Docetaxel—skin cancer	0.000181	0.000837	CcSEcCtD
Pioglitazone—Diarrhoea—Docetaxel—skin cancer	0.000173	0.000798	CcSEcCtD
Pioglitazone—Dizziness—Docetaxel—skin cancer	0.000167	0.000772	CcSEcCtD
Pioglitazone—Headache—Docetaxel—skin cancer	0.000158	0.000731	CcSEcCtD
